Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 19,132 | 16,008 | 48 | 97 | 26,127 |
| Receivables | 414 | N/A | N/A | N/A | N/A |
| Inventories | 279 | 52 | N/A | N/A | N/A |
| TOTAL | $20,106 | $16,146 | $48 | $97 | $26,127 |
| Non-Current Assets | |||||
| PPE Net | 381 | 236 | N/A | N/A | N/A |
| Other Non-Current Assets | 23 | 23 | 0 | 0 | 0 |
| TOTAL | $404 | $258 | $N/A | $N/A | $N/A |
| Total Assets | $20,510 | $16,404 | $48 | $97 | $26,127 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,380 | 1,487 | 33 | 10 | 3,289 |
| Accrued Expenses | 669 | 92 | 5 | N/A | N/A |
| TOTAL | $2,303 | $1,579 | $38 | $10 | $3,289 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 254 | N/A | N/A | N/A | N/A |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,303 | $1,579 | $38 | $10 | $3,289 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 60,301 | 49,502 | 39,422 | 1,917 | N/A |
| Common Shares | 60 | 49 | 8 | 2 | 1,283 |
| Retained earnings | -26,347 | -13,072 | -184 | -105 | -39,652 |
| TOTAL | $18,207 | $14,824 | $10 | $87 | $22,838 |
| Total Liabilities And Equity | $20,510 | $16,404 | $48 | $97 | $26,127 |